These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 3452642)

  • 1. [Low-dose cytosine arabinoside therapy in relapsed acute leukemia: correlation of clinical response and in vitro sensitivity tests].
    Ninomiya T; Hirose M; Takaue Y; Watanabe T; Ouchi T; Sato J; Koyama T; Abe T; Suzue T
    Rinsho Ketsueki; 1987 Oct; 28(10):1763-70. PubMed ID: 3452642
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of cytosine arabinoside on cell kinetics in adult acute leukemia and its correlation to the therapeutic response].
    Furusawa S; Adachi Y; Nomura T; Komiya M
    Rinsho Ketsueki; 1972 Dec; 13(6):943-50. PubMed ID: 4675065
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Balwierz W; Juraszewska E; Matysiak M; Malinowska I; Stanczak E; Sońta-Jakimczyk D; Szczepanski T; Wachowiak J; Konatkowska B; Balcerska A; Ploszynska A; Kowalczyk J; Stefaniak J; Badowska W; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M
    Neoplasma; 2005; 52(1):74-8. PubMed ID: 15739031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
    Ohshima A; Yoshida K; Sato T; Miyazaki S; Yanagisawa M; Nakayama Y; Takahashi T; Mamiya S; Fukusima Y; Miura AB
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High-dose cytosine arabinoside in acute leukemia: a cooperative study].
    Urabe A; Takaku F; Mizoguchi H; Yamada O; Wakabayashi Y; Miura Y; Sakamoto S; Yoshida M; Miwa S; Asano S
    Rinsho Ketsueki; 1985 Feb; 26(2):184-8. PubMed ID: 3894715
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
    Takahashi I; Yorimitsu S; Inagaki T; Sekito N; Hayashi N; Nishimura M; Aoyama S; Nakada H; Ohmoto E; Uchida K
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High-dose cytosine arabinoside therapy in refractory acute leukemia].
    Yorimitsu S; Takahashi I; Kitazima K; Kimura I; Hara M; Tokuda M
    Rinsho Ketsueki; 1984 Dec; 25(12):1941-6. PubMed ID: 6533329
    [No Abstract]   [Full Text] [Related]  

  • 8. [High-dose cytosine arabinoside and L-asparaginase in the treatment of refractory or recurrent acute non-lymphoblastic leukemia].
    Sanz MA; Borrego D; Martín-Aragonés G; Martínez JA; Lorenzo I; Sanz G; Sayas MJ; Jarque I; Pastor E; Rafecas J
    Sangre (Barc); 1987; 32(4):476-81. PubMed ID: 3660187
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cytosine-arabinoside in the treatment of acute leukemias].
    Böhnel J; Gingold N; Hermansky F; Pawlowski M; Stacher A
    Wien Med Wochenschr; 1972 Apr; 122(15):203-7. PubMed ID: 4527321
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].
    Saito K; Furusawa S; Yamada K; Waga K; Aoyagi A; Koike T; Arimura H; Noguchi M; Yamato H; Sakuma H
    Rinsho Ketsueki; 1995 Mar; 36(3):165-74. PubMed ID: 7540220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Induction of cellular differentiation in the treatment of acute leukemias: preliminary report of the use of low doses of cytosine arabinoside for the induction of remission].
    Marín-López A; Lobato-Mendizábal E; Munive-Ordóñez I; Ruiz-Argüelles GJ
    Rev Invest Clin; 1984; 36(3):247-51. PubMed ID: 6515157
    [No Abstract]   [Full Text] [Related]  

  • 12. [Induction of remission by sequential treatment with cytosine arabinoside (araC/high dose) and L-asparaginase].
    Martín-Aragonés G; Sanz MA; Martínez JA; Rafecas FJ; Gomis F; Lorenzo I; Sanz G; Marty ML
    Sangre (Barc); 1985; 30(1):15-21. PubMed ID: 3859023
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy with cytosine arabinoside and daunomycin in childhood acute leukemia].
    Tsukimoto I; Mimaya J; Toyosaka H; Nagao T; Hanawa Y
    Rinsho Ketsueki; 1973 May; 14(5):596-603. PubMed ID: 4738276
    [No Abstract]   [Full Text] [Related]  

  • 15. Growth response of residual leukemia after initial drug therapy.
    Karp JE; Burke PJ
    Cancer Res; 1986 Aug; 46(8):4205-7. PubMed ID: 3731087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.
    Bern MM; Wallach SR; Arkin CF; Lokich JJ; Huberman MS; Anderson NR; Corkery JC; Paul SD; Phillips DF; Sonneborn HA
    Cancer Treat Rep; 1987 Feb; 71(2):201-3. PubMed ID: 3802115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enhanced sensitivity to cytosine arabinoside by combined stimulation of steel factor and GM-CSF in a factor-dependent leukemic cell line, MO7e--in terms of a possible clinical application to AML treatment].
    Gotoh A; Kawanishi Y; Kurosawa K; Miyazawa K; Ohtaka M; Aizawa S; Kimura Y; Yoshikawa O; Toyama K
    Rinsho Ketsueki; 1993 Jul; 34(7):821-8. PubMed ID: 7689660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-dose cytosine arabinoside administration in the treatment of refractory leukemia].
    Yoshida M; Furukawa Y; Akashi M; Komatsu N; Takeda K; Muroi K; Ikeda K; Ohsaka A; Ohta M; Suda K
    Rinsho Ketsueki; 1985 Aug; 26(8):1258-64. PubMed ID: 3865002
    [No Abstract]   [Full Text] [Related]  

  • 19. Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukaemias.
    Uckun FM; Morar S; Qazi S
    Br J Haematol; 2006 Nov; 135(4):500-8. PubMed ID: 17061978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.